Advertisement
Canada markets closed

  • S&P/TSX

    23,866.27
    +273.67 (+1.16%)
     

  • S&P 500

    5,713.64
    +95.38 (+1.70%)
     

  • DOW

    42,025.19
    +522.09 (+1.26%)
     

  • CAD/USD

    0.7376
    +0.0023 (+0.31%)
     

  • CRUDE OIL

    72.07
    +0.12 (+0.17%)
     

  • Bitcoin CAD

    85,191.95
    +3,455.23 (+4.23%)
     

  • XRP CAD

    0.79
    +0.01 (+1.01%)
     

  • GOLD FUTURES

    2,611.20
    -3.40 (-0.13%)
     

  • RUSSELL 2000

    2,252.71
    +46.37 (+2.10%)
     

  • 10-Yr Bond

    3.7400
    +0.0550 (+1.49%)
     

  • NASDAQ futures

    19,829.75
    -20.50 (-0.10%)
     

  • VOLATILITY

    16.33
    -1.90 (-10.42%)
     

  • FTSE

    8,328.72
    +75.04 (+0.91%)
     

  • NIKKEI 225

    37,155.33
    +775.16 (+2.13%)
     

  • CAD/EUR

    0.6605
    -0.0004 (-0.06%)
     
MARKETS LIVE BLOG:

STOCKS SURGE AS FED CHAIR FIRES UP RALLY

Rate-sensitive growth stocks climb, with Big Tech megacaps making gains

Hims & Hers offers compounded Wegovy for $99 a month to select professions

Amina Niasse
·2 min read
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London

By Amina Niasse

NEW YORK (Reuters) - U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.

The company said the pricing would be available to eligible U.S. military members, teachers, nurses and first responders, including police and firefighters, as well as veterans. For patients on a 12-month plan, Hims offers a semaglutide injection for $199 a month, according to its website.

WHY IT'S IMPORTANT

The news comes after U.S. Senator Bernie Sanders said multiple generic drugmakers confirmed they could sell custom-made versions of Novo's drug for less than $100 a month using the semaglutide.

Soaring demand for weight-loss drugs in the GLP-1 class, which have been shown to help patients lose as much as 20% of their weight on average, has led to shortages of the drugs that have allowed compounders to produce them under U.S. regulations.

Around 70% of U.S. adults are either overweight or obese, According to the World Health Organization (WHO).

CONTEXT

Ozempic and Wegovy carry high list prices of $935.77 and $1,349.02 respectively for a month's supply, according to the company's website. Most U.S. patients are covered by health insurance and would likely pay less for the drugs.

Novo and rival Eli Lilly, which makes the weight-loss drug Zepbound, have filed a flurry of lawsuits against medical spas, wellness clinics and compounding pharmacies for allegedly selling products claiming to contain the active ingredients in their drugs.

Compounded GLP-1 injections are fulfilled and shipped from Hims & Hers' affiliated pharmacies and are FDA-regulated, the company said.

KEY QUOTE

“The current state of access to weight loss drugs isn’t serving everyone who needs them,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “Safe and affordable healthcare solutions for every individual should be the status quo."

(Reporting by Amina Niasse in New York; Editing by Patrick Wingrove and Aurora Ellis)